CliffBio
small molecule

WAYRILZ

RILZABRUTINIB

Loss of exclusivityFebruary 2041latest FDA-listed patent expiry
CompanyGenzyme →See this company's full patent-cliff portfolio

Drug detail

Brand nameWAYRILZ
Active ingredientRILZABRUTINIB
Strength400MG
Dosage formTABLET
RouteORAL
ModalitySmall molecule
FDA approvalAugust 2025
Marketing statusRX

Listed patents

PatentExpiresType
11708370February 2041substance
12178818October 2040use U-4267
9994576September 2033substance, product
9266895September 2033substance, product
8940744September 2033substance, product
9580427March 2033substance, product

Regulatory exclusivity

CodeExpires
ODE-552August 2032
NCEAugust 2030

More from Genzyme

Source: FDA Orange Book, layered on the CliffBio company graph. Cliff dates are the latest FDA-listed patent expiry; estimates are projections, not legal advice.

WAYRILZ patent cliff — loss of exclusivity February 2041 | CliffBio